Health> Vol.6 No.9, March 2014

Resource Constraints as a Barrier to Lung Cancer Management: Developing Nations

DownloadDownload as PDF (Size:1009KB)  HTML    PP. 845-851  

ABSTRACT

Resource constraints are a major barrier to lung cancer management, especially in ASIAN developing countries. The availability of data in these issues is very limited. Therefore, this survey was initiated in order to understand the situation of resource constraints in ASIAN developing nations. A 17-item, self-administered, online questionnaire was developed and distributed to IASLC members in ASIAN countries in May-June 2013. A questionnaire was composed of 2 sections: general and specific information focusing on several issues related to resource constraints such as lagging period of new cancer drug approval, economic data submission, man power, availability and accessibility to diagnosis and treatment, waiting time, and payment. There were a total of 75 respondents from China, India, Indonesia, Malaysia, Nepal, Philippines, and Thailand. The findings of this survey demonstrate that ASIAN developing countries still need the improvement in their resources such as man power, diagnostic procedures, and treatment especially new agents like targeted drugs.

Cite this paper

Thongprasert, S. and Permsuwan, U. (2014) Resource Constraints as a Barrier to Lung Cancer Management: Developing Nations. Health, 6, 845-851. doi: 10.4236/health.2014.69106.

References

[1] International Agency for Research on Cancer. GLOBOCAN. (2012) Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
[2] Knaul, F.M., Anderson, B., Bradley, C. and Kerr, D. (2010) Access to Cancer Treatment in Low- and Middle-Income Countries. An Essential Part of Global Cancer Control.
http://papers.ssm.com/sol3/papers.cfm?abstract_id=2055441
[3] Macbeth, F.R., Abratt, R.P., Choc, K.H., Stephens, R.J. and Jeremice, B. (2007) International Atomic Energy Agency Lung Cancer Management in Limited Resource Settings: Guidelines for Appropriate Good Care. Radiotherapy and Oncology, 82, 123-131.
http://dx.doi.org/10.1016/j.radonc.2006.12.006
[4] Berry, S.R., Evans, W.K., Strevel, E.L. and Bell, C.M. (2012) Variation and Constemation: Access to Unfunded Cancer Drugs in Canada. Journal of Oncology Practice, 8, 135-139.
http://dx.doi.org/10.1200/JOP.2011.000278
[5] Farmer, P., Frenk, J., Knaul, F.M., Shulman, L.N., Alleyne, G., Armstrong, L., et al. (2010) Expansion of Cancer Care and Control in Countries of Low and Middle Income: A Call to Action. Lancet, 376, 1186-1193.
http://dx.doi.org/10.1016/S0140-6736(10)61152-X
[6] Pickles, H. (1997) Treating Lung Cancer in the NHS Market. British Medical Journal, 315, 1548.2.

comments powered by Disqus

Copyright © 2014 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.